

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6561925

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
LITING GUO	11/14/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CRYSTAL PHARMATECH CO., LTD.
<b>Street Address:</b>	B4-101, BIOBAY, 218 XINGHU STREET
<b>Internal Address:</b>	INDUSTRIAL PARK
<b>City:</b>	SUZHOU
<b>State/Country:</b>	CHINA
<b>Postal Code:</b>	215123
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16765456
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)607-9200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 449-6590
<b>Email:</b>	cgjordani@mccarter.com
<b>Correspondent Name:</b>	MCCARTER & ENGLISH, LLP
<b>Address Line 1:</b>	265 FRANKLIN STREET
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	128748-00403
<b>NAME OF SUBMITTER:</b>	MEI BAI, PH.D.
<b>SIGNATURE:</b>	/Mei Bai/
<b>DATE SIGNED:</b>	02/20/2021
<b>Total Attachments: 11</b>	
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page1.tif	
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page2.tif	
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page3.tif	
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page4.tif	
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page5.tif	

source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page6.tif  
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page7.tif  
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page8.tif  
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page9.tif  
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page10.tif  
source=AGI-PKR-16WO ASSIGNMENT - Liting Guo to Crystal Pharmatech Co#page11.tif

ASSIGNMENT

I, Liting Guo, a Chinese citizen, of Qinshui Langting Blvd. 18, 2 HongFan Road, Suzhou, Jiangsu 215000, China (hereinafter the "Undersigned"), was previously employed at Crystal Pharmatech Co., Ltd, having a place of business at Suite 101, Bldg. B4, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou 215123, China,

whereas I am an inventor for the International Application for Patent (hereinafter the "Patent Application") to be filed with the United States Patent and Trademark Office as Receiving Office of the World Intellectual Property Organization in accordance with the Patent Cooperation Treaty (PCT) entitled **CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE**, claiming priority to U.S. Provisional Application Serial Number 62/589,822 filed November 22, 2017 and U.S. Provisional Application Serial Number 62/691,709 filed June 29, 2018.

my contributions to the conception of the inventions and improvement claimed and disclosed in the Patent Application were made during the course of my employment at Crystal Pharmatech, Co. Ltd, I do hereby state:

with no compensation, ASSIGN to Crystal Pharmatech Co., Ltd, (hereinafter the "Assignee"), the Undersigned's entire right, title and interest throughout the world in the inventions and improvements which are subject of this Patent Application including:

the inventions disclosed in the Patent Application;

the Patent Application, and all divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other applications for a patent or patents which have been or shall be filed in the United States, and in all foreign countries and jurisdictions based in whole or in part on any of the said inventions and improvements (including any application for a utility model, design registration(s), and inventor's certificate(s));

the right to claim priority to the Patent Application in relation to subject matter based in whole or in part on the above-identified application(s) and any of the foregoing under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

the right to file in my name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventor's certificate(s) for said inventions and improvements in the United States and all foreign countries under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and

the right to all causes of action, remedies, and other enforcement rights related to the above-identified application(s), including without limitation the right to sue for past, present, or future infringement, misappropriation, or violation of any and all rights related to the above-

identified application(s) and any of the foregoing, including the right to obtain and collect damages for past, present, or future infringement.

The Undersigned agrees the U.S. and foreign patent issuing authority to issue any and all United States and foreign patents (including any application for a utility model, design registrations, and inventor's certificate(s)) on the said inventions and improvements to the Assignee.

Since the Undersigned has assigned the above-mentioned rights for the patent Application, the Undersigned will not be liable for any cost or damage suffered by Assignee related to the Patent. Meanwhile, Assignee will assume all responsibility and risk related to the Patent Application.

The Undersigned covenants, that should the execution date, filing date and/or Application Number be not entered or be incorrect at the time the Undersigned executed this document, the Undersigned hereby authorizes and requests an attorney of Assignee to insert the information or make the correction.

This contract is written in Chinese and English. If there are any inconsistencies, the Chinese version should control.

IN TESTIMONY WHEREOF, I, Liting Guo, have executed this document on the date indicated below.

(Signature of Liting Guo)  
Signature of Inventor

November 14, 2018  
Date

\_\_\_\_\_  
Inventor's City, State of Residence

**Witnessed by:**

(1) \_\_\_\_\_  
Signature of Witness

\_\_\_\_\_  
Date

\_\_\_\_\_  
Print Witness Name

\_\_\_\_\_  
Witness' City and Country of Residence

(2) \_\_\_\_\_  
Signature of Witness

\_\_\_\_\_  
Date

\_\_\_\_\_  
Print Witness Name

\_\_\_\_\_  
Witness' City and Country of Residence

ACCEPTED AND AGREED TO BY ASSIGNEE: CRYSTAL PHARMATECH CO., LTD:

Signature: (Signature of Minhua Chen) Date: November 14, 2018

Printed Name: \_\_\_\_\_

Title: \_\_\_\_\_

(Seal of CRYSTAL PHARMATECH CO., LTD. 3200000003890)

(Special Seal for Translation Business of Global Tone Communication Technology Co., Ltd. 1101070152720)

# Notarial Certificate

(Translation)

(2018)J.Z.X.W.J.Z.Zi. No.01446

The applicant: Guo Liting, female, born on [REDACTED] ID No.

[REDACTED]

The applicant: Crystal Pharmatech Co., Ltd, Unified Social Credit Code: [REDACTED] Address: Suite 101, Bldg. B4, Biobay, 218 Xinghu Street, Suzhou Industrial Park

Legal Representative: Chen Minhua, male, born on [REDACTED] ID No. [REDACTED]

Notarial Affairs: Signature and seal

This is to certify that the signature of Guo Liting, the seal of Crystal Pharmatech Co., Ltd and the signature of legal representative Chen Minhua affixed on the ASSIGNMENT attached hereto are found to be authentic.



Notary: Liu Ying

Zhongxin Notary Public Office

Beijing

The People's Republic of China

Nov. 14, 2018

111111111111

# 公 证 书

(2018)京中信外经证字01447号

申请人：郭丽婷，女，一九[ ]年[ ]日出生，  
公民身份号码：[ ]。

申请人：苏州晶云药物科技股份有限公司，统一社会信用  
用代码：[ ]，住所：苏州工业园区星湖街  
218号生物纳米园B4-101。

法定代表人：陈敏华，男，一九[ ]年[ ]日出  
生，公民身份号码：[ ]。

公证事项：译本与原本相符


兹证明前面的(2018)京中信外经证字01446号《公证  
书》的英文译本内容与该公证书中文原本相符。

中华人民共和国北京市中信公证处

公证员

刘莹

二〇一八年十一月十四日



# Notarial Certificate

(Translation)

(2018)J.Z.X.W.J.Z.Zi. No.01447

The applicant: Guo Liting, female, born on [REDACTED] ID No.

[REDACTED]  
The applicant: Crystal Pharmatech Co., Ltd, Unified Social Credit  
Code: [REDACTED] Address: Suite 101, Bldg. B4, Biobay, 218  
Xinghu Street, Suzhou Industrial Park

Legal Representative: Chen Minhua, male, born on [REDACTED]  
ID No. [REDACTED]

Notarial Affairs: the translation is in conformity with the original

This is to certify that the English translation of the Notarial  
Certificate (2018) J.Z.X.W.J.Z.Zi. No. 01446 attached hereto is in  
conformity with the Chinese original.

Notary: Liu Ying

Zhongxin Notary Public Office

Beijing

The People's Republic of China

Nov. 14, 2018



11/17/2018

PATENT  
REEL: 055347 FRAME: 0626



# 公 证 书

中华人民共和国北京市中信公证处

PATENT  
REEL: 055347 FRAME: 0627

## 转让书

本人郭丽婷（中国国籍），住址位于中国江苏省苏州市虹范路2号沁水朗庭18幢，邮编215000（以下简称为“签署人”），此前受雇于晶云药物科技有限公司，其营业地点位于中国苏州市工业园区星湖街218号生物医药产业园B4幢101室，邮编215123。

鉴于本人为根据《专利合作条约》(PCT)的规定将向世界知识产权组织的接收机构美国专利商标局提出的专利名称为CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE的国际专利申请（以下简称为“专利申请”）的发明人，该申请要求2017年11月22日提交的第62/589,822号临时申请和2018年6月29日提交的第62/691,709号美国临时申请的优先权。

本人在专利申请书中声明和披露的发明概念和改良是在受雇于晶云药物科技有限公司时的成果。

本人特此声明：

无偿将本人在世界范围内与该专利申请书主题的发明和改良相关的所有权利、所有权和利益转让至晶云药物科技有限公司（以下简称为“受让人”）包括：

专利申请书中披露的发明；

该专利申请，和所有已经或应当在美国和其他所有其他国家和司法辖区申请的基于上述任何完整或部分发明和改良的专利的所有分案申请、继续申请（包括部分继续申请）、代替申请、续期申请、再授权申请和所有其他申请（包括任何实用新型、外观设计和发明人证书的申请）；

根据《保护工业产权国际公约》、《专利合作条约》、《欧洲专利公约》和其他类似目的条约下，要求与基于全部或部分上述申请或任何前述申请的主题有关的上述申请的优先权；

在美国和《保护工业产权国际公约》、《专利合作条约》、《欧洲专利公约》和其他类似目的条约下的所有其他国家，就上述发明和改良以本人名义或其自身名义申请专利、实用新型、外观设计和类似专属权利和发明人证书；

与上述申请相关的所有诉因、救济权和其他执行权利，包括但不限于对过去、现在或未来的任何侵权、滥用和违反提起诉讼的权利，及与上述和任何前述申请相关的所有权利，包括就过去、现在或未来的任何侵权收取和获得违约金的责任。

签署人同意美国和其他国家专利授权机构向受让人授予与上述发明和改良相关的任何及所有美国和国外专利（包括实用新型、外观设计和发明人证书的申请）。

转让书


Page 1 of 3

鉴于签署人已转让该专利申请的上述权利, 签署人将不负责承担受让人产生的与该专利相关的任何成本或赔偿, 同时受让人将承担与该专利相关的所有责任和风险。

签署人立约承诺, 如果在签署人签署本文件时, 还未填写签署日期和申请日期, 和/或申请编号有误, 签署人特此授权受让人律师可以输入相关信息或进行纠正。

本合同用中英文两种版本书写, 如有不一致, 以中文版为准。

本人, 郭丽婷, 已在下文所述日期签署本文件, 特此证明。

  
.....  
发明人签名

2018.11.14  
.....  
日期

.....  
发明人居住州和城市

见证人:

(1) .....  
见证人签名

.....  
日期

.....  
见证人打印姓名

.....  
见证人居住国家和城市

(2) .....  
见证人签名


.....  
日期

.....  
见证人打印姓名

.....  
见证人居住国家和城市



受让人接受并同意: 晶云药物科技有限公司




签名: \_\_\_\_\_

日期: \_\_\_\_\_

2018/11/14

打印姓名: \_\_\_\_\_

职称: \_\_\_\_\_



# 公 证 书

(2018)京中信外经证字01446号

申请人：郭丽婷，女，一九[ ]年[ ]日出生，  
公民身份号码：[ ]

申请人：苏州晶云药物科技股份有限公司，统一社会信用  
代码：[ ]，住所：苏州工业园区星湖街  
218号生物纳米园B4-101。

法定代表人：陈敏华，男，一九[ ]年[ ]日出  
生，公民身份号码：[ ]

公证事项：签名、印鉴

兹证明前面的《转让书》上郭丽婷之签名及苏州晶云药  
物科技股份有限公司之印鉴、法定代表人陈敏华之签名均属  
实。

中华人民共和国北京市中信公证处

公证员

刘莹

二〇一八年十一月十四日

